tetano
Editor, Senior Moderator
Emerg Microbes Infect
. 2020 Dec;9(1):1096-1101.
doi: 10.1080/22221751.2020.1766382.
Delayed Specific IgM Antibody Responses Observed Among COVID-19 Patients With Severe Progression
Liang Shen[SUP] 1 [/SUP], Chunhua Wang[SUP] 1 [/SUP], Jianzhong Zhao[SUP] 1 [/SUP], Xiaoyong Tang[SUP] 1 [/SUP], Ying Shen[SUP] 1 [/SUP], Mingqing Lu[SUP] 2 [/SUP], Zhe Ding[SUP] 2 [/SUP], Canping Huang[SUP] 2 [/SUP], Ji Zhang[SUP] 1 [/SUP], Shichao Li[SUP] 1 [/SUP], Jiaming Lan[SUP] 2 [/SUP], Gary Wong[SUP] 2 3 [/SUP], Yufang Zhu[SUP] 1 [/SUP]
Affiliations
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread rapidly worldwide since it was confirmed as the causative agent of COVID-19. Molecular diagnosis of the disease is typically performed via nucleic acid-based detection of the virus from swabs, sputum or bronchoalveolar lavage fluid (BALF). However, the positive rate from the commonly used specimens (swabs or sputum) was less than 75%. Immunological assays for SARS-CoV-2 are needed to accurately diagnose COVID-19. Sera were collected from patients or healthy people in a local hospital in Xiangyang, Hubei Province, China. The SARS-CoV-2 specific IgM antibodies were then detected using a SARS-CoV-2 IgM colloidal gold immunochromatographic assay (GICA). Results were analysed in combination with sera collection date and clinical information. The GICA was found to be positive with the detected 82.2% (37/45) of RT-qPCR confirmed COVID-19 cases, as well as 32.0% (8/25) of clinically confirmed, RT-qPCR negative patients (4-14 days after symptom onset). Investigation of IgM-negative, RT-qPCR-positive COVID-19 patients showed that half of them developed severe disease. The GICA was found to be a useful test to complement existing PCR-based assays for confirmation of COVID-19, and a delayed specific IgM antibody response was observed among COVID-19 patients with severe progression.
Keywords: COVID-19; GICA; IgM antibody; delayed; severity.
. 2020 Dec;9(1):1096-1101.
doi: 10.1080/22221751.2020.1766382.
Delayed Specific IgM Antibody Responses Observed Among COVID-19 Patients With Severe Progression
Liang Shen[SUP] 1 [/SUP], Chunhua Wang[SUP] 1 [/SUP], Jianzhong Zhao[SUP] 1 [/SUP], Xiaoyong Tang[SUP] 1 [/SUP], Ying Shen[SUP] 1 [/SUP], Mingqing Lu[SUP] 2 [/SUP], Zhe Ding[SUP] 2 [/SUP], Canping Huang[SUP] 2 [/SUP], Ji Zhang[SUP] 1 [/SUP], Shichao Li[SUP] 1 [/SUP], Jiaming Lan[SUP] 2 [/SUP], Gary Wong[SUP] 2 3 [/SUP], Yufang Zhu[SUP] 1 [/SUP]
Affiliations
- PMID: 32476607
- DOI: 10.1080/22221751.2020.1766382
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread rapidly worldwide since it was confirmed as the causative agent of COVID-19. Molecular diagnosis of the disease is typically performed via nucleic acid-based detection of the virus from swabs, sputum or bronchoalveolar lavage fluid (BALF). However, the positive rate from the commonly used specimens (swabs or sputum) was less than 75%. Immunological assays for SARS-CoV-2 are needed to accurately diagnose COVID-19. Sera were collected from patients or healthy people in a local hospital in Xiangyang, Hubei Province, China. The SARS-CoV-2 specific IgM antibodies were then detected using a SARS-CoV-2 IgM colloidal gold immunochromatographic assay (GICA). Results were analysed in combination with sera collection date and clinical information. The GICA was found to be positive with the detected 82.2% (37/45) of RT-qPCR confirmed COVID-19 cases, as well as 32.0% (8/25) of clinically confirmed, RT-qPCR negative patients (4-14 days after symptom onset). Investigation of IgM-negative, RT-qPCR-positive COVID-19 patients showed that half of them developed severe disease. The GICA was found to be a useful test to complement existing PCR-based assays for confirmation of COVID-19, and a delayed specific IgM antibody response was observed among COVID-19 patients with severe progression.
Keywords: COVID-19; GICA; IgM antibody; delayed; severity.